AI is beginning to transform biologics discovery. The power of algorithms used in biologics discovery has increased over the last decade, and today between 50 and 60 AI-enabled biologics are in different stages of discovery, preclinical and clinical development. We expect the number of AI-enabled biologics to continue to grow rapidly, driven by advances in AI technology and algorithms, growing computing power, increasing availability of data, and evolving discovery workflows. We show that the volume of data used for training algorithms in biologics discovery is increasing exponentially over time, a trend reminiscent of Moore’s Law in computer technology.
Artificial intelligence (AI) and machine learning are revolutionizing drug discovery. Over the last five to ten years the main focus has been on small molecules, where we are seeing strong growth in the number of compounds discovered using AI technologies.
In parallel, but less well-known, AI is beginning to transform other areas of drug discovery, most importantly biologics (protein and...
A discussion with Karen Harris, CFO of the Alzheimer's Drug Discovery Foundation, about the foundation's investment strategy, biotech and investor sentiment at the recent BIO conference and what innovations give her hope for Alzheimer's patients.
While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.
UK biotech targets the root cause of metabolic disease while preserving muscle mass in a crowded obesity market.
Qubit Pharmaceuticals and Sorbonne University launched a quantum AI model that could slash drug synthesis requirements and enable exploration of previously undruggable targets.
MedTech Forum 2025 was less MDR-focused than in previous years, as macro issues and exogenous threats were forced further into the center of medtech business thinking.
In a conversation with In Vivo, CEO Jon Congleton discusses Mineralys’s data-rich journey toward an NDA filing, the significance of recent trial wins and how its candidate may offer a dual benefit in blood pressure and renal protection.
Qubit Pharmaceuticals and Sorbonne University launched a quantum AI model that could slash drug synthesis requirements and enable exploration of previously undruggable targets.
